Dynorphin(1-13) improves survival in cats with focal cerebral ischaemia.
Since the discovery of opiate receptors in the central nervous system (CNS), it has become apparent that endogenous opiate ligands are involved in CNS function. Most attention has focused on their role in modulating pain, but they have also been implicated in various physiological functions and in disease states. We are concerned with evidence that endogenous opioid peptides may also contribute to the neurological deficits arising from cerebral ischaemia. Dynorphin, which is widely distributed in the brain and pituitary, has been reported to produce unusual motor and behavioural effects and may act as a regulatory neuropeptide, not as a classical opiate agonist or antagonist. We have therefore administered to cats in which the right middle cerebral artery had been occluded both dynorphin (1-13) and analogue and control materials. We find that dynorphin (1-13) prolongs survival.
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D002415:Cats; D004399:Dynorphins / Q000494:pharmacology / Q000627:therapeutic use*; D004743:Enkephalin, Leucine / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*
D010446:Peptide Fragments; D004743:Enkephalin, Leucine; C026843:dynorphin (1-13); D004399:Dynorphins